Izilendustat hydrochloride is a potent prolyl hydroxylase inhibitor that stabilizes hypoxia-inducible factor-1α (HIF-1α) and hypoxia-inducible factor-2 (HIF-2); it has potential for the treatment of HIF-1α-related diseases, including peripheral vascular disease (PVD), coronary artery disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases.